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Abstract 
Background: CRAd-S-pk7 is a conditionally replicative oncolytic adenoviral vector that contains a survivin promoter 
and a pk7 fiber modification that confer tumor-specific transcriptional targeting and preferential replication in glioma 
while sparing the surrounding normal brain parenchyma.
Methods: This IND-enabling study performed under GLP conditions evaluated the toxicity and biodistribution of 
CRAd-S-pk7 administered as a single intracerebral dose to Syrian hamsters, a permissive model of adenoviral repli-
cation. Two hundred and forty animals were stereotactically administered either vehicle (n = 60) or CRAd-S-pk7 at 
2.5 × 107, 2.5 × 108, or 2.5 × 109 viral particles (vp)/animal (each n = 60) on day 1. The animals were closely moni-
tored for toxicology evaluation, assessment of viral distribution, and immunogenicity of CRAd-S-pk7.
Results: Changes in hematology, clinical chemistry, and coagulation parameters were minor and transient, and 
consistent with the inflammatory changes observed microscopically. These changes were considered to be of little 
toxicological significance. The vector remained localized primarily in the brain and to some degree in the tissues at 
the incision site. Low levels of vector DNA were detected in other tissues in a few animals suggesting systemic circula-
tion of the virus. Viral DNA was detected in brains of hamsters for up to 62 days. However, microscopic changes and 
virus-related toxicity to the central nervous system were considered minor and decreased in incidence and severity 
over time. Such changes are not uncommon in studies using adenoviral vectors.
Conclusion: This study provides safety and toxicology data justifying a clinical trial of CRAd-S-pk7 loaded in FDA-
approved HB1.F3.CD neural stem cell carriers administered at the tumor resection bed in humans with recurrent 
malignant glioma.
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Background
Despite recent advances in glioma treatments such as 
surgical resection, chemotherapies, and novel drug thera-
pies, the survival rate of patients with advanced-grade 
glioma remains dismal [1]. For that matter, the desperate 
clinical context of high-grade glioma warrants the pre-
sent development of novel strategies with the potential 
for direct patient impact. An emerging, highly promising 
strategy for the treatment of glioma is the delivery of spe-
cific therapeutic agent(s) to tumor areas such as oncolytic 
viruses, aptly termed, oncolytic virotherapy [1–4].
Among the oncolytic viruses, human adenovirus 
serotype 5 (Ad5) is the most commonly used due to its 
well-studied biology and flexibility for genetic modifica-
tions [2, 3]. By taking advantage of these characteristics, 
a conditionally replicating oncolytic adenovirus, CRAd-
S-pk7, has been generated [5]. This viral vector infects 
cells by binding to anionic cell surface proteins through 
seven lysine residues (pk7) on the adenoviral fiber [6, 7] 
and subsequently initiates replication by way of E1 gene 
expression under the control of the tumor-specific pro-
moter survivin (S) [5]. This glioma selective oncolytic 
agent, CRAd-S-pk7, was shown to efficiently lyse glioma 
cells while sparing non-neoplastic cells [8, 9]. However, 
the efficacy of CRAd-S-pk7 in the clinical setting can be 
nullified via both immune surveillance and pre-existing 
neutralizing antibodies against Ad5 [8, 9]. Moreover, the 
biodistribution of oncolytic viruses (OVs) may be limited 
to the outer borders of a solid tumor mass with robust 
vascular supply, which often results in inconsistent viral 
penetration to the center of the tumor mass [8–10].
To surmount these problems, we employed a cell car-
rier approach with neural stem cells (NSCs), which were 
shown to have a natural tropism toward tumor cells and 
the capability to penetrate the center of the tumor mass 
[8–11]. In our previous studies, we showed that NSCs 
loaded with CRAd-S-pk7 could travel toward the tumor 
cells while simultaneously protecting CRAd-S-pk7 from 
immune surveillance as well as acting as host cells for 
CRAd-S-pk7 progeny production [8–12]. Furthermore, 
NSCs loaded with CRAd-S-pk7 could be delivered 
into the center of the tumor mass and lyse tumor cells 
more efficiently than virus administration alone, which 
accounted for a significant survival benefit in xenograft 
murine models of GBM [1, 8–12].
Given the fact that the murine model is not permissive 
to replication of human adenoviruses [13–15], we herein 
investigated the biodistribution and toxicology of CRAd-
S-pk7 after intracerebral administration of the therapeutic 
viral agent into Syrian Hamsters. This study was conducted 
under FDA guidelines, using Good Laboratory Practice 
(GLP) throughout, and will be used in filing of the final 
Investigational New Drug  (IND). This Syrian Hamster 
model is permissive for human adenovirus replication and 
is fully immune competent [9, 15], so the replication pro-
files and immune responses in different organs after the 
administration of this vehicle can recapitulate the replica-
tion kinetics and the toxicity of CRAd-S-pk7 in the human 
clinical setting. For this analysis, we administered single 
intracerebral doses of 2.5 × 107, 2.5 × 108, and 2.5 × 109 
viral particles (vp) per animal. These doses were established 
based on our preclinical analysis using 50 vp/cell of CRAd-
S-pk7 per 5 × 105 NSCs (2.5 × 107 vp/hamster in total) [9].
In the immunological analysis, antibody response 
against E1 of the vector was observed in a dose-depend-
ent manner as expected. Pathologically, minimal and 
transient reactive inflammatory changes were observed at 
all dose levels, which were not toxicologically significant. 
Furthermore, the viral vector was predominantly local-
ized to the brain, with low levels of vector DNA observed 
in other tissues. Presence of vector in tissues was not cor-
related with any microscopic changes or vector-mediated 
toxicity. In summary, we demonstrated that the agreeable 
safety profile of CRAd-S-pk7 justifies proceeding with a 
planned Phase I clinical trial, utilizing this agent loaded 
onto FDA-approved NSCs for patients with GBM.
Methods
Animals
Syrian hamsters (Haslett, MI, USA) (n = 250) were ran-
domized by body weight into one of four groups (groups 
2–5) comprised of 120 male and 120 female hamsters dis-
tributed in equal numbers into core and satellite groups 
(60 male and 60 female hamsters each) (Table 1). The core 
groups (15 animals/sex/group) were used for toxicology 
evaluations including hematology and clinical chemis-
try, and the satellite groups (15 animals/sex/group) were 
used for assessment of the biodistribution and immuno-
genicity of the test article (CRAd-S-pk7) as well as the 
effect on coagulation parameters. Of note, 5 male and 
5 female hamsters were arbitrarily placed into Group 1. 
They remained untreated and were used on day 1 for col-
lection of baseline immunogenicity samples, after which 
they were removed from the study without further evalu-
ation. All hamsters were approximately 5–6 weeks old on 
arrival at Southern Research (Birmingham, AL, USA) and 
the study was approved by the Institutional Animal Care 
and Use Committee. The hamsters in groups 2–5 were 
given an intracerebral injection of vehicle [GST150 Buffer 
(20  mM Tris, 150  mM NaCl, 2.5  % (w/v) glycerol, pH 
8.0)] or CRAd-S-pk7 at 2.5 × 107, 2.5 × 108, or 2.5 × 109 
viral particles (vp)/animal, respectively, at a fixed vol-
ume on day 1. Blood samples were drawn on days 6, 34, 
or 62 prior to necropsy from 5 male and 5 female ham-
sters from each of the core groups for the assessment of 
hematology and clinical chemistry parameters/analytes, 
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and from another five male and five female hamsters in 
the satellite groups for the assessment of coagulation 
parameters.
Clinical observations
All animals were observed at least twice daily during the 
pre-study and study periods for signs of mortality and 
moribundity.
Body weights and food consumption
All animals were weighed on day 1 and randomly 
assigned to each group. During the test periods, each ani-
mal was weighed weekly. Quantitative food consumption 
was measured weekly beginning on day 1 for each animal 
in the core group. Values were reported as an average 
consumption (grams/animal/day).
Tissue preservation and processing
Following injection of viral particles (2.5 × 107, 2.5 × 108, 
and 2.5 ×  109, respectively), five male and female ham-
sters per group were sacrificed at 6, 34, and 62  days. 
Whole brains, as well as other organs, were collected 
for tissue bio-distribution analysis. Tissues (bone mar-
row (bilateral femurs; flushed), gonads, heart, incision 
site (skin, subcutis, muscle), kidneys, liver, lungs, mesen-
teric lymph nodes, and spleen) were snap frozen in liquid 
nitrogen and stored at −70 °C until analysis.
Viral DNA and transcript detection in the brain
Five male and five female animals per group were sacri-
ficed at 6, 34, and 62 days. Whole brains were collected 
for detection and quantification of viral DNA at each 
time point. Tissues were snap frozen in liquid nitrogen 
and stored at −70 °C, or colder, until analysis. Brain tis-
sue was analyzed for viral DNA via quantitative PCR 
(qPCR), using an assay previously evaluated and validated 
at Southern Research Institute. Tissue was homogenized 
and DNA was extracted using the Qiagen QIA amp 96 
DNA QIAcube HT Kit (Qiagen, Venlo, The Netherlands). 
Samples were analyzed in triplicates, with one replicate 
spiked with 100 copies of adenovirus DNA to evaluate 
for possible inhibitors. The Qiagen QuantiTect Multiplex 
Master Mix was used for all qPCR reactions (Qiagen, 
Venlo, The Netherlands). Primers, probe, and control 
DNA were added to each reaction to serve as an inter-
nal amplification control and to rule out inhibition. DNA 
concentration was measured by spectrophotometer. The 
probes and primers used were validated specifically for 
human adenovirus serotype five hexon gene.
All brains were analyzed on days 6 and 34. Only those 
positive for vector DNA on day 34 were analyzed on day 
62. PCR analysis was conducted using Applied Biosys-
tems 7900HT Fast Real-Time PCR System (Applied Bio-
systems, Foster City, CA, USA) with software SDS 2.2.2. 
Settings used were: activation at 95  °C for 15  min, 45 
cycles of denaturing at 95 °C for 10 s, and annealing/elon-
gation at 60 °C for 45 s.
Systemic biodistribution of virally encoded transcripts 
after CRAd‑S‑pk7 intracerebral injection
On the planned day of necropsy, five male and five female 
animals in the satellite groups 2–5 were anesthetized and 
blood samples (~0.5 mL) were collected from the retro-
orbital sinus into anticoagulant tubes (EDTA). Sam-
ples were mixed by gentle inversion, then snap frozen 
on dry ice and stored at −70  °C or below until analysis. 
Table 1 Assignment of hamsters to study groups
Thirty hamsters per sex were assigned to each of four dose groups, and were administered one intracerebral injection on day 1 of either vehicle (group 2) or the 
test article at 2.5 × 107 , 2.5 × 108, or 2.5 × 109 viral particles (vp)/animal (groups 3, 4, and 5, respectively). Of these animals, 15 animals/sex/group (core groups) 
were used for toxicology evaluations including hematology and clinical chemistry, and the remaining animals (satellite groups) were used for assessment of the 
biodistribution and immunogenicity of the test article as well as the effect on coagulation parameters. In addition, five untreated animals per sex (group 1) were used 
on day 1 for collection of baseline immunogenicity samples, after which they were removed from the study without further evaluation
VP viral particles, M males, F females
a The low, mid, and high vector doses were selected to bracket the expected human clinical range of 6.8 × 1010 to 2.06 × 1011 vp/dose, with doses scaled based on 
the relative brain weights of the two species (hamster ≈ 0.001 × human)




Core groups Satellite groups












1 Untreated 0 – – – 5 M/5 F – – –
2 Vehicle 0 5 M/5 F 5 M/5 F 5 M/5 F – 5 M/5 F 5 M/5 F 5 M/5 F
3 Vector low 2.5 × 107 5 M/5 F 5 M/5 F 5 M/5 F – 5 M/5 F 5 M/5 F 5 M/5 F
4 Vector mid 2.5 × 108 5 M/5 F 5 M/5 F 5 M/5 F – 5 M/5 F 5 M/5 F 5 M/5 F
5 Vector high 2.5 × 109 5 M/5 F 5 M/5 F 5 M/5 F – 5 M/5 F 5 M/5 F 5 M/5 F
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The animals were then euthanized and the following 
whole tissues were collected: bone marrow, femur (both; 
flushed), brain, gonads (ovary/testis), heart, incision site 
(skin, subcutis, muscle), kidney, liver, lungs, lymph nodes, 
mesentery, and spleen. Tissue samples were snap frozen 
in liquid nitrogen and stored at −70 °C in the same fash-
ion as blood samples. Blood and tissues collected were 
assayed for the presence of vector DNA using a qPCR 
protocol previously evaluated and validated at Southern 
Research Institute. Tissue was homogenized and DNA 
was extracted using the Qiagen QIA amp 96 DNA QIA-
cube HT Kit (Qiagen, Venlo, The Netherlands). Samples 
were analyzed in triplicates, with one replicate spiked 
with 100 copies of adenovirus DNA to evaluate for pos-
sible inhibitors. The Qiagen QuantiTect Multiplex Mas-
ter Mix was used for all qPCR reactions (Qiagen, Venlo, 
The Netherlands). Primers, probe and control DNA were 
added to each reaction to serve as an internal amplifica-
tion control and to rule out inhibition. DNA concentra-
tion was measured by spectrophotometer. The probes 
and primers used were validated specifically for human 
adenovirus serotype five hexon gene.
Since brain was the only tissue positive for vector 
DNA at day 34, blood and other tissue samples were not 
assayed at day 62. PCR analysis was conducted using 
Applied Biosystems 7900HT Fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA) with software SDS 
2.2.2. Settings used were: activation at 95 °C for 15 min, 
45 cycles of denaturing at 95  °C for 10 s and annealing/
elongation at 60 °C for 45 s.
Blood collection
On days 6, 34, and 62 post-injection, blood samples were 
collected prior the euthanasia for hematology and clinical 
chemistry evaluation from each hamster scheduled for 
necropsy. On these days blood was also collected from 
each hamster in satellite groups for evaluation of coagu-
lation prior to euthanasia. Blood was collected from each 
hamster from the retro-orbital sinus using tubes contain-
ing either EDTA as an anticoagulant for hematology, or 
no coagulant for clinical chemistry, or sodium citrate 
as an anticoagulant for coagulation evaluation. Tubes 
were mixed by gentle inversion upon collection. Clinical 
pathology samples were analyzed on the same day that 
the samples were obtained. The following hematology 
parameters were assayed: total leukocyte count, erythro-
cyte count, hemoglobin, hematocrit, mean corpuscular 
volume, mean corpuscular hemoglobin, mean corpuscu-
lar hemoglobin concentration, reticulocyte count, plate-
let count, differential leukocyte counts, RBC morphology, 
and nucleated red blood cell count. The following clinical 
chemistry parameters were assayed: urea nitrogen, aspar-
tate aminotransferase, alanine aminotransferase, alkaline 
phosphatase, glucose, creatinine, creatine kinase, total 
protein, albumin, globulin (calculated), albumin/globu-
lin ratio (calculated), sodium, potassium, chloride, cho-
lesterol, total bilirubin, calcium, phosphorus, blood urea 
nitrogen (BUN)/creatinine ratio (calculated). For coagu-
lation analysis, prothrombin time and fibrinogen were 
assayed.
Immunogenicity
Control blood samples for immunogenicity analysis 
(~0.5 mL) were collected on day 1 from five animals per 
sex in the untreated group. Terminal blood samples were 
collected from satellite group animals on days 6, 34, and 
62 immediately after blood collection for biodistribution. 
Samples were collected into tubes without anticoagulant. 
Serum was frozen and stored at −70  °C until analysis. 
One aliquot of each sample was assayed for antibodies 
against the vector using an ELISA assay developed and 
validated for GLP use at Southern Research.
Histopathology and toxicity
In the pathologic evaluation of CRAd-S-pk7 when 
administered as a single intracerebral dose in hamsters, 
viral toxicity was assessed through both gross and micro-
scopic evaluations. Half of the animals were used for 
tissue collection for histopathology and the remaining 
satellite animals were used for biodistribution  studies. 
The doses of  vectors administered to groups 2 through 
5, respectively, were: 0 (vehicle), 2.5 × 107 (vector, low), 
2.5 × 108 (vector, mid), or 2.5 × 109 (vector, high). Ani-
mals were then euthanized on days 6, 34, and 62 and 
examined post-mortem.
For each post-mortem pathologic examination at 
the respective time points, all tissues were examined 
both grossly and microscopically. Hematoxylin and 
eosin (H&E) staining was performed on formalin-fixed 
paraffin-embedded (FFPE) tissue for histopathological 
evaluation. In addition to the standard tissue evalua-
tion, target organs (brain and cervical spinal cord) were 
evaluated on day 34 and any gross lesions were docu-
mented, examined, and histologically graded on day 
62. Lesions were graded according to their degree of 
involvement.
Microscopic lesions observed in this study were graded 
using a numerical scoring system in which 1 = minimal, 
2  =  mild, 3  =  moderate, and 4  =  marked. In general, 
lesions that affected less than 10 % of the tissue were con-
sidered as minimal, lesions that affected 11–50 % of tissue 
were considered as mild, lesions that affected 51–75 % of 
tissue were considered to as moderate, and lesions that 
affected greater than 75  % of tissue were considered as 
marked. All graded pathological evaluation was blinded 
to treatment.
Page 5 of 14Kim et al. J Transl Med  (2016) 14:134 
Statistical analyses
For CRAd-S-pk7 dose effect analyses, cytotoxicity and 
clinical pathology data among four groups (groups 2, 3, 
4, and 5) were compared. When the equality of variances 
among the groups assumption holds, One-way analysis of 
variance (ANOVA) with post hoc Bonferroni correction 
for multiple comparison were used. When the variances 
among the groups were not equal, Kruskal–Wallis test 
with post hoc Mann–Whitney U tests with the Bonfer-
roni correction were performed. Linear regression mod-
els were conducted to assess the effect of the four groups 
on viral copies with log10 transformed. Generalized Esti-
mating Equation approach was used to estimate the 
parameters in the regression models taking into account 
the longitudinal structure of the data. For the hematol-
ogy, clinical chemistry, and coagulation parameters/ana-
lytes, the individual’s percent change (%Δ) on each day of 
analysis relative to the vehicle group’s (i.e., group 2) mean 
for the time point by sex was calculated with the follow-
ing formula: %Δ in parameter/analyte for individual on 
day X = [(individual’s day X value − Y)/Y] × 100, where 
X = days 6, 34, or 62 and Y = vehicle group mean value 
for day X by sex and time point. Statistical analyses were 
performed with the statistical analysis system (SAS) soft-
ware Version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
In vivo effects of CRAd‑S‑pk7 in a permissive 
immunocompetent animal model
The human adenovirus serotype five was genetically 
modified to enhance its infectivity and to restrict its rep-
lication to glioma as shown in Fig. 1. CRAd-S-pk7 infects 
cells by binding to anionic cell surface proteins through 
seven lysine residues (pk7) on the adenoviral fiber and 
subsequently initiating replication by way of E1 gene 
expression under the control of the tumor-specific pro-
moter, survivin [4, 16]. To investigate the overall health 
changes on test subjects, we administered this thera-
peutic viral agent intracerebrally to Syrian hamsters, a 
human adenovirus replication-permissive animal model, 
in single doses (Table 1) and monitored mortality, clinical 
signs, food consumption, and body weight. Although a 
few animals showed scabs at the surgical site, those scabs 
were considered to be related to the surgical procedure. 
Therefore, there was no dose-related pattern associated 
with this observation. Only CRAd-S-pk7-treated female 
hamster groups showed a tendency to consume less food 
at most time points than the vehicle control female group 
did (days 1–8: groups 2 vs. 4, P 0.032; groups 2 vs. 5, P 
0.027; days 8–15: groups 2 vs. 5, P 0.009; days 15–22: 
groups 3 vs. 5, P 0.01; one-way ANOVA, respectively). 
However, this tendency was not considered to be biologi-
cally significant. Also, there was no observable effect on 
body weights of CRAd-S-pk7-administered hamsters in 
this study (P  >  0.05, one-way ANOVA, Kruskal–Wallis 
test when appropriate) (Fig. 2). 
Detection of viral DNA in the brain
Identification and quantitative analysis of viral DNA in 
the brain was performed to assess the ability of the virus 
to replicate and persist for the duration of the study 
period. The viral transcripts present were compared in 
the brains of control, vehicle-treated, and virus-treated 
animals via tissue homogenization, DNA extraction, and 
Fig. 1 Schematic of genome of CRAd-S-pk7. The fiber knob domain has seven lysine residues added to the C-terminal end to enhance the infectiv-
ity of the virus. The essential early replication gene (E1) is under the transcriptional control of the tumor-specific promoter survivin (S) to restrict viral 
replication to tumor cells (oncolysis)
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qPCR as described in the methods section. Viral DNA 
was not detectable in the brains of control and vehicle-
treated animals for the duration of the study. Dose-
dependent copies of viral DNA were found in the brains 
of all animals receiving treatment, with the exception 
of one in the 2.5 ×  108 vp/animal group, at 6  days. All 
brain tissues remained positive for viral DNA at 34 and 
62  days, P  <  0.0001, G2 vs. G3/4/5, one-way ANOVA. 
There was a decrease in viral DNA detected by 1–2 
orders of magnitude when comparing days 6 and 34 
(102−4 vs. 100−1.5) in both male and female hamsters, G2 
vs. G3/4/5, P = 0.0002 and P < 0.0001, one-way ANOVA, 
respectively. However, a relevant amount of virus was still 
present on day 34 when comparing vehicle and treatment 
groups (G2 vs. G3/4/5, P < 0.0001, one-way ANOVA). In 
addition, there was a significant decline in the viral DNA 
present from days 34 to 62 in female (101.5 vs. 100, G2 vs. 
G5, P  <  0.0001, one-way ANOVA) and male hamsters 
(101 vs. 100, G2 vs. G3/4, P < 0.0001, one-way ANOVA) 
(Fig. 3).
Systemic biodistribution of virally encoded transcripts 
after CRAd‑S‑pk7 intracerebral injection
Evaluation for viral DNA in the blood and systemic tis-
sues was performed to determine viral distribution, 
replication, and potential toxicity in off-target tissues. 
All samples from animals treated with the control vehi-
cle remained negative for vector DNA throughout the 
study. In the satellite groups receiving test article, vector 
DNA was detected in various peripheral tissues on day 
6 (Fig. 4). It was detected in the liver (9 × 102 copies/μg 
of DNA, P < 0.05 vs. IS 100 copies/μg of DNA, one-way 
ANOVA), spleen (3  ×  102 copies/μg of DNA, P  <  0.05 
vs. IS), and bone marrow (9  ×  100 copies/μg of DNA, 
P > 0.05 vs. IS) in one male from the 2.5 × 108 vp/animal 
dose group. This animal had no detectable vector DNA in 
the brain or other tissues. Analysis of additional animals 
revealed two females in the 2.5  ×  108 vp/animal dose 
group (6 ×  101 viral copies/μg of DNA in the blood vs. 
6.3 × 101 at IS, P > 0.05; 6 × 102 copies/μg of DNA in the 
blood vs. 4 × 101 at IS, P < 0.05, one-way ANOVA) and 
Fig. 2 Body weight and food consumption for male and female hamsters. Administration of CRAd-S-pk7 had no significant effect on body weight 
or food consumption for male hamsters (P > 0.05, one-way ANOVA). In the female group, a significant difference was noted concerning decreased 
food consumption on days 1–8: groups 2 vs. 4, P 0.032; groups 2 vs. 5, P 0.027; days 8–15: groups 2 vs. 5, P 0.009; days 15–22: groups 3 vs. 5, P 0.01; 
one-way ANOVA. However, this tendency was not considered to be biologically significant. The analyzed measurements are shown as g for body 
weight and g/animal/day for food consumption. Each plot represents the average of 5–10 animals/sex/group/time point and standard deviations 
were indicated by error bars. One-way ANOVA and Kruskal–Wallis test were used for comparison between vehicle (G2) and treated (G3-5) groups. 
*P < 0.05
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three males (7 × 101 viral copies/μg of DNA in the blood 
vs. 9 × 102 at IS, P < 0.05; 9 × 101 copies/μg of DNA in 
the blood vs. 100 at IS, P  <  0.05, 2  ×  102 copies/μg of 
DNA in the blood vs. 8 ×  102 at IS, P  <  0.05, one-way 
ANOVA) and one female in the 2.5 × 109 vp/animal dose 
group (9 ×  101 viral copies/μg of DNA in the blood vs. 
100 at IS, P < 0.05) that had viral vectors detected in the 
blood. One male in the 2.5 × 109 vp/animal dose group 
had viral DNA detected in the lungs (2.7 × 101 viral cop-
ies/μg of DNA in the lung vs. 100 at IS, P < 0.05); and one 
male in the 2.5 × 109 vp/animal dose group had viral vec-
tors present in the bone marrow (8 × 100 viral copies/μg 
of DNA in the BM vs. 8 ×  102 at IS, P < 0.05, one-way 
ANOVA). On day 34, only brain samples were positive 
for vector DNA. The day 6 results indicate that the vector 
was able to enter the systemic circulation in a small num-
ber of animals. In these cases, viral particles were found 
largely in expected organs, those with robust vascular 
supply and known depot or scavenger function. Further, 
the presence of vector was not correlated with any micro-
scopic changes in the tissues that would suggest toxicity 
after CRAd-S-pk7 intracerebral injection. The absence of 
microscopic changes in these organs confirms the speci-
ficity of the vector for glioma, with no sequelae of infec-
tion in other tissues.
Hematological and clinical chemistry analyses 
of CRAd‑S‑pk7 treatment
To determine whether administration of CRAd-S-pk7 
elicited an inflammatory response, WBC, neutrophil, 
monocyte counts, as well as coagulation and other 
hematology parameters were obtained from peripheral 
blood samples. Clinical chemistry parameters were also 
assessed in order to evaluate potential adverse effects 
of CRAd-S-pk7 treatment. No significant differences 
in WBC, neutrophil, monocyte counts, or other hema-
tological parameters were observed between vehicle 
and treatment groups for most groups, P  >  0.05, one-
way ANOVA. Although a slight increase in monocyte 
counts was observed in male hamsters from group 5 and 
female hamsters from group 3 on day 6 after treatment, 
the difference was not statistically significant as com-
pared to the vehicle control group (G2) (P =  0.15, one-
way ANOVA). In addition, such an increase in monocyte 
counts was not detected at later time points. Although 
elevated WBC, neutrophil, and monocyte counts rela-
tive to published reference levels were observed in some 
animals, there was no clear implication that CRAd-S-pk7 
administration was related to the increased cell counts. 
These results suggest that there is no significant inflam-
matory response to the administration of CRAd-S-pk7. 
CRAd-S-pk7 also does not affect coagulation param-
eters, as no significant changes in fibrinogen levels or 
prothrombin were observed at any time point in ham-
sters that were administered with any dose of CRAd-S-
pk7 compared to control (P  >  0.05, one-way ANOVA) 
(Fig. 5a–f).
Likewise, in almost all clinical chemistry parameters 
measured (urea nitrogen, aspartate aminotransferase, 
alanine aminotransferase, alkaline phosphatase, glucose, 
creatinine, creatine kinase, total protein, albumin, glob-
ulin (calculated), albumin/globulin ratio (calculated), 
sodium, potassium, chloride, cholesterol, total biliru-
bin, calcium, phosphorus, blood urea nitrogen (BUN)/
creatinine ratio (calculated)) at any time point, there 
was no observable difference between any of the groups 
Fig. 3 Mean vector DNA in the brains. Brain tissues of male and female hamsters were analyzed for the presence of CRAd-S-pk7 DNA post virus 
injection. Intracerebral CRAd-S-pk7 DNA was found 6 days after injection in both sexes (G2 vs. G3/4/5, P < 0.0001, one-way ANOVA), whereas DNA 
detection decreased gradually by days 32 and 64 by at least one order of magnitude (G2 vs. G3/4 for male hamsters, P < 0.0001, one-way ANOVA, 
and G2 vs. G5 for female hamsters, P < 0.0001, one-way ANOVA). The analyzed measurements are shown as log10 (viral copies/ng × 1000). Each plot 
represents the average of five animals/sex/group/time point and standard deviations were indicated by error bars. One-way ANOVA and Kruskal–
Wallis test were used for comparison between vehicle (G2) and treated (G3-5) groups. ***P < 0.001
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(P > 0.05, one-way ANOVA). In addition, serum albumin 
was significantly decreased in male hamsters adminis-
tered the highest vector dose (2.5 × 109 vp/animal, G5) 
at day 6 (3.22 ± 0.13 in G5 vs. 3.02 ± 0.08 in G2, P < 0.05, 
one-way ANOVA). However, the effect size was small 
and not considered to be of biological importance (data 
no shown).
Induction of a moderate IgG antibody response 
with CRAd‑S‑pk7 treatment
We next sought to investigate the immunogenicity of 
CRAd-S-pk7 by determining serum antibody responses 
to Ad-E1a in control and treatment hamsters across 
all three time points. No Ad-E1a antibody response 
was  observed in untreated hamsters or vehicle-treated/
G2 hamsters. Furthermore, no Ad-E1a antibody response 
was observed in hamsters treated with any dose level of 
CRAd-S-pk7 at day 6, P > 0.05, one-way ANOVA. Ani-
mals treated with 2.5  ×  108 and 2.5  ×  109 vp/animal 
(the middle/G4 and high/G5 vector doses) exhibited 
increased anti-AdE1a antibody titers in a dose-depend-
ent manner on days 34 and 62 in both males (on day 
34: 1.6 for G2 vs. 2.7 for G4, P < 0.0001; and 1.6 for G2 
vs. 3 for G5, P < 0.0001; on day 62: 1.6 for G2 vs. 2.3 for 
G4, P = 0.0062; and 1.6 for G2 vs. 3.2 for G5, P < 0.0001, 
one-way ANOVA) and females (on day 34: 1.6 for G2 
vs. 2.7 for G4, P = 0.002; and 1.6 for G2 vs. 3.5 for G5, 
P < 0.0001; on day 62: 1.6 for G2 vs. 2.8 for G4, P = 0.004; 
and 1.6 for G2 vs. 3.6 for G5, P  <  0.0001, one-way 
ANOVA). In animals treated with the low vector dose of 
2.5 × 107 vp/animal, viral titers were close to background 
levels on both days 34 and 62, P < 0.05. These data sug-
gest that intracerebral injection of CRAd-S-pk7 vector 
results in a marginal IgG immune response for the vector 
at low doses and a stronger IgG immune response for the 
middle and high dose groups (Fig. 6).
Gross and microscopic histopathological analyses
To determine if viral vector treatment caused any 
significant pathology, hamsters were sacrificed at 
Fig. 4 Biodistribution of vector DNA. Quantitative PCR values for mean copies per reaction and mean copies per μg of DNA for systemic organs and 
tissues at day 6 after vector administration. Tissues listed are those positive for viral DNA in each animal. Animals are delineated by group number 
and gender. The analyzed measurements are shown as mean copies per sample in the log10 scale. Each plot represents the average of duplicate 
samples and standard deviations are indicated by error bars. One-way ANOVA and Kruskal–Wallis test were used for comparison between viral 
copies in different organs/blood and those present at the injection site. *P < 0.05. G4 Vector mid 2.5 × 108 vp/animal, G5 vector high 2.5 × 109 vp/
animal, IS injection site, BM bone marrow
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predetermined time points (days 6, 34, and 62), and all 
organs were first observed macroscopically before fixa-
tion/sectioning/H&E staining for microscopic analysis. 
Standard gross pathologic evaluation revealed no asso-
ciated pathogenesis as a result of viral vector toxicity 
(Additional file  1: Table  S1). There was focal inflamma-
tion at the injection sites of all treatment groups, includ-
ing the vehicle cohort, which suggests that most of the 
gross inflammatory effects were due to the mechani-
cal trauma of the procedure rather than the therapeutic 
Fig. 5 Evaluation of inflammatory response to CRAd-S-pk7 administration over time. Cell counts for total white blood cells (WBC) (a, b) neutrophils 
(c, d), and monocytes (e, f) were determined from the peripheral blood of both male and female hamsters in vehicle and vector-treated groups on 
days 6, 34, and 62 for the doses shown (n = 5 animals/group). The analyzed measurements are shown as number of cells per mm3 (×103). Standard 
deviations are indicated by error bars. One-way ANOVA and Kruskal–Wallis test were used for comparison of cell counts between animals from 
vehicle (G2) and treated (G3-5) groups; ns, P > 0.05
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agent (Additional file 1: Table S2). Microscopically, there 
were treatment-related effects observed in some animals. 
On day 6, there was chronic perivascular and meningeal 
inflammation, including a cytopathic effect consisting 
of eosinophilic intranuclear inclusions, consistent with 
adenoviral infection in the brain. Both acute and chronic 
inflammation was noted along with histiocytic inflamma-
tory infiltrates. Mild to moderate chronic inflammation 
was observed in the meninges along with mild to mod-
erate chronic perivascular inflammation in the brains of 
most animals of all test article groups (Additional file 1: 
Table  S2). Minimal chronic perivascular inflammation 
was observed in the cervical, thoracic, and lumbar spinal 
cords (and meninges) of select high vector animals (data 
not shown). Mild perivascular inflammation was also 
observed in the pituitary glands (pars nervosa) of such 
high vector animals. The occurrence of cells with large, 
smudged nuclei and atypical nuclear contours along with 
occasional intranuclear inclusions was also observed in 
the brains of select animals. Microscopic evaluation on 
day 34 revealed similar or lessened chronic inflammatory 
patterns that were further reduced by Day 62 (Additional 
file 1: Table S2; Fig. 7).
Analysis of lethality and toxicity towards organs 
and tissues
To demonstrate that CRAd-S-pk7 did not result in ani-
mal death and/or organ-specific toxicity, a study cohort 
set of 30 hamsters of each sex per group (120 males and 
120 females) was evaluated with regard to clinical signs 
and symptoms associated with the treatment. All ham-
sters were sacrificed at their pre-determined endpoints 
with no clinically relevant manifestations (Table 2). Also, 
hematological studies and clinical chemistry work-up did 
not show evidence of viral toxicity either. Anatomic path-
ological evaluation revealed reactive regenerative mor-
phologic changes resultant from mechanical trauma due 
to the intracerebral injection of the viral vector and cyto-
pathic effects consistent with cellular adenoviral infec-
tion, although no diagnostic anomalies associated with 
vector toxicity were observed. No morbidity or mortal-
ity was experienced in animals prior to their sacrificial 
endpoints, demonstrating that no lethality resulted from 
the test article. This is consistent with the anatomic and 
pathological studies that demonstrated no identifiable 
vector-mediated toxicity in any animals of all test groups.
Discussion
We have previously demonstrated the effectiveness of 
CRAd-S-pk7 as a single or combined therapy against 
high-grade gliomas [4, 11, 17–19]. As compared with 
other oncolytic viruses, CRAd-S-pk7 showed the high-
est level of viral replication and tumor oncolysis in GBM 
cell lines, with minimal toxicity to normal brain tissue 
[4, 11, 18]. Intracranial injection of CRAd-S-pk7 alone 
reduced tumor growth by 300 and 67  % of treated ani-
mals were long-term survivors [4, 11, 18]. Synergistic 
effect of CRAd-S-pk7 with the current standard of care 
for anti-glioma therapy, radiotherapy and temozolo-
mide, was also positively validated in animal models [17, 
19]. Taken together, these findings provide the rationale 
for further application of this tumor-specific oncolytic 
virus in a phase 1 clinical trial in patients with recurrent 
high-grade glioma. In preparation for this, herein we 
evaluated the biodistribution, toxicology, and anti-viral 
immune response of CRAd-S-pk7 in Syrian Hamsters, an 
Fig. 6 Moderate dose-dependent antibody response to CRAd-S-pk7 administration. Serum anti-AdE1a antibody titer was determined in both male 
and female hamsters (a, b) on days 6, 34, and 62 after initial treatment for the doses shown (n = 5 animals/group). The analyzed measurements are 
shown as group geometric mean titers in the log10 scale. One-way ANOVA and Kruskal–Wallis test were used for comparison of E1A antibody titers 
between animals from vehicle control (G2) and treatment (G3-5) groups; ***P < 0.001. Values of the group geometric mean titer were rounded to 
the nearest whole number. For the calculation of the geometric mean, when the titer was <400 (the lower limit of detection in this assay), a value of 
40 (1/10th of 400) was used
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immunocompetent model that is permissive for the repli-
cation of human adenoviruses [11]. We observed that fol-
lowing intracranial administration of vehicle or low, mid, 
or high doses of the test article formulation of CRAd-
S-pk7 (2.5 × 107, 2.5 × 108, or 2.5 × 109 viral particles/
animal, respectively), viral particles were largely confined 
to the brain. Low levels of vector DNA were detected in 
other tissues in a few animals suggesting that  systemic 
circulation of the virus can occur. Microscopic changes 
and virus-related toxicity were considered minor and 
CRAd-S-pk7 intracerebral injection was not associ-
ated with lethality. In addition, CRAd-S-pk7 was able to 
elicit measurable dose-dependent IgG immune response 
by day 34 after intracranial injection, which was consid-
ered to be marginal in the lowest dose group. In sum, the 
above results provide safety and toxicology data justify-
ing the clinical application of CRAd-S-pk7 in humans 
with recurrent malignant glioma.
Concerning virus biodistribution, 6  days after intrac-
ranial administration, viral genomic DNA was present 
in the brains of all animals at all time-points, with the 
exception of one animal. The levels of vector DNA in the 
Fig. 7 Histological analysis of samples associated with CRAd-S-pk7 adenoviral vector delivery over time. Assessment of histopathological changes 
on CNS tissues associated with adenoviral vector treatment. Vector high dose group (1 × 109) is shown. In a minor amounts of meningitis perivas-
cular inflammation were detected in the treatment groups, which subsided by 62 days post treatment. In b minor inflammation of the thalamus 
and its associated vasculature occurred in select animals; which also subsided by 62 days post treatment. Quantification of events is outlined in 
Additional file 1: Table S2. For histological examination, we used 10 hamsters per group per time point
Table 2 Survival of animals treated with CRAd-S-pk7 viral 
vector after intracranial injection
Regardless of titer of vector treatment, all animals made it to their 












Day 6 10/10 10/10 10/10 10/10 100
Day 34 10/10 10/10 10/10 10/10 100
Day 62 10/10 10/10 10/10 10/10 100
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brains were dose-dependent and decreased over time, 
with a maximum decrease observed between days 6 and 
34 after intracranial injection. The persistence of virus 
DNA 62  days after local administration was consistent 
with low levels of inflammation observed at the viral dis-
tribution sites. The significant time-dependent decrease 
of vector DNA in the brains of the studied animals was 
consistent with previous reports showing that these 
conditionally replicative adenovirus vectors are tumor-
specific and do not replicate in non-malignant brain tis-
sues [3, 4, 9, 11, 18, 20, 21]. Systemic dissemination of 
intracranially administered CRAd-S-Pk7 was assessed in 
immunocompetent hamsters by qPCR. Blood was col-
lected and various organs were harvested from animals 
sacrificed 6, 34, and 62 days after virus injection. On day 
6, vector DNA was present at low levels at the incision 
site of many animals as well as in the blood and other tis-
sues of a few animals in the mid and high-dose groups. 
The presence of vector DNA in these non-brain/incision 
site tissues indicated that for a few animals the vector 
was able to enter the systemic circulation. However, there 
were no microscopic lesions in these tissues from core 
group animals on day 6, suggesting that the presence of 
vector DNA in extraneural tissues was of no toxicologi-
cal significance. Moreover, vector DNA was not detected 
in tissues outside the brain after day 6. These results are 
consistent with previously published data and confirm 
the safety and limited biodistribution of CRAd-S-pk7 
after intracranial administration [11].
The toxicological profile of CRAd-S-pk7 after intrac-
ranial administration was assessed via local and periph-
eral inflammatory response, measured mainly by 
immune cell count, fibrinogen and albumin levels, and 
macro- and microscopic pathological changes in har-
vested tissues at the above described time points. At 
all dose levels there was an increase in total leukocyte, 
neutrophil, and/or monocyte counts and fibrinogen lev-
els, and a significant decrease in mean albumin level for 
male hamsters in the high dose group on day 6. We also 
observed microscopic inflammatory lesions in the brain, 
spinal cord, and meninges for hamsters of both sexes at 
all three time points (days 6, 34, and 62). However, these 
observed changes in clinical pathology parameters were 
for the most part present at relatively low levels. Moreo-
ver, there were no clinically significant test article-related 
inter-group differences for male hamsters on days 34 or 
62, suggesting recovery from the adverse effects seen on 
day 6. There were no apparent test article-related inter-
group differences for female hamsters at any time point. 
Therefore, the observed changes in clinical pathology 
parameters were considered to be of little toxicological 
significance other than as possible indicators of the 
underlying inflammation occurring in the nervous sys-
tem. Considering additional toxicological parameters, we 
did not observe any changes in body weight between the 
studied groups. Changes in hematology, clinical chem-
istry, and coagulation parameters were minor and tran-
sient, and were consistent with the inflammatory changes 
that were observed microscopically. These changes were 
considered of little toxicological significance.
In terms of immune reactions, CRAd-S-pk7 was able 
to elicit a measurable IgG immune response at all dose 
levels by day 34. The magnitude of this response was 
related to the dose, with the response in the low dose 
group considered to be marginal. Because the levels of 
anti-CRAd-S-pk7 antibodies  were higher in the high 
dose group than in  the mid dose  on both days 34 and 
62, it was not possible from the data in this study to say 
whether a maximal response had been reached at the 
high dose. Based on previous reports and the above-
described data, it is expected that CRAd-S-pk7 may 
induce anticancer immunity through viral replication 
followed by tumor cell lysis in glioma-bearing subjects 
[22–24]. However, modulating the immune response can 
be tricky and a fine balance between antiviral and anti-
tumor immune responses must be achieved so that the 
virus will be able to first infect and lyse the tumor cells 
and then induce an antitumor immune response against 
neighboring malignant tissues.
In summary, administration of CRAd-S-pk7 at dif-
ferent doses produced a positive antibody response 
against the virus. The vector remained localized pri-
marily in the brain and to some degree in the tissues at 
the incision site, although the presence of low levels of 
virus DNA in other tissues indicated that the vector was 
able to enter the systemic circulation in a few animals. 
However, the presence of virus  in those tissues from 
the satellite group animals was not correlated with any 
microscopic changes in the same tissues of core group 
animals that would suggest toxicity of the vector. Test 
article-related microscopic changes were observed that 
were consistent with viral disease affecting the central 
nervous system; these changes appeared to decrease 
in incidence and severity over time, indicating that 
recovery was in progress. Because of the microscopic 
changes seen in the 2.5  ×  107 vp/animal group, a no 
observed adverse effect level (NOAEL) could not be 
identified for the CRAd-S-pk7 vector under the condi-
tions of this study. These results provide feasibility data 
related to the biodistribution, toxicology, and immune 
response of CRAd-S-pk7 in preparation for a phase 1 
clinical trial.
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Conclusion
This study provides safety and toxicology data justifying 
a clinical trial of CRAd-S-pk7 loaded in FDA-approved 
HB1.F3.CD neural stem cell carriers administered at the 
tumor resection bed in humans with recurrent malignant 
glioma.
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